B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory

DBCOND0089403B-cell Malignancy Bone Marrow Diseases

B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: refractory B-cell chronic lymphocytic leukemia
Classified under: B-cell Malignancy
Bone Marrow Diseases
Hematologic Neoplasms
Hemic and Lymphatic Disease, Unclassified
Immunoproliferative Disorders
Lymphatic Disorders
Indicated drugs: Fludarabine

Resolves to

Vocabularies

MedDRA10003894UMLSC0855097

What you can answer from here — as of October 07, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

1Clinical trialPhase, status and sponsor resolved per trial

Which approved drugs for B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account